Skip to main navigation Skip to search Skip to main content

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

  • Kevin R. Kelly
  • , Jonathan W. Friedberg
  • , Steven I. Park
  • , Kevin McDonagh
  • , John Hayslip
  • , Daniel Persky
  • , Jia Ruan
  • , Soham Puvvada
  • , Peter Rosen
  • , Swaminathan Padmanabhan Iyer
  • , Alexandra Stefanovic
  • , Steven H. Bernstein
  • , Steven Weitman
  • , Anand Karnad
  • , Gregory Monohan
  • , Ari VanderWalde
  • , Raul Mena
  • , Monika Schmelz
  • , Catherine Spier
  • , Susan Groshen
    • Karthik Venkatakrishnan, Xiaofei Zhou, Emily Sheldon-Waniga, E. Jane Leonard, Daruka Mahadevan

Research output: Contribution to journal › Article › peer-review

31   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases